ID

13564

Descripción

Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00081822

Link

https://clinicaltrials.gov/show/NCT00081822

Palabras clave

Versiones (1)
  1. 16/2/16 16/2/16 -
Titular de derechos de autor

CC BY-NC 3.0

Subido en

16 de febrero de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Acute Myeloid Leukemia NCT00081822

Inglés

Eligibility Acute Myeloid Leukemia NCT00081822

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
have newly diagnosed aml (fab classification types m0-m2 or m4-m7 or who classification) excluding acute promyelocytic leukemia (apl) or aml with any of the following chromosomal translocations: t(15;17)(q22;q21); t(11;17)(q23;q21); t(11;17)(q13;q21); t(5;17)(q32;q12)..
Descripción

have newly diagnosed aml (fab classification types m0-m2 or m4-m7 or who classification) excluding acute promyelocytic leukemia (apl) or aml with any of the following chromosomal translocations: t(15;17)(q22;q21); t(11;17)(q23;q21); t(11;17)(q13;q21); t(5;17)(q32;q12)..

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023467
UMLS CUI [2]
C0023487
UMLS CUI [3]
C3688712
UMLS CUI [4]
C1515708
UMLS CUI [5]
C2825131
have greater than or equal to 20% blasts in the bone marrow.
Descripción

have greater than or equal to 20% blasts in the bone marrow.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1982687
have greater than or equal to 20% cellularity in the bone marrow.
Descripción

have greater than or equal to 20% cellularity in the bone marrow.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1561532
provide written informed consent.
Descripción

provide written informed consent.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
must be 60-75 years of age at diagnosis.
Descripción

must be 60-75 years of age at diagnosis.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
have an karnofsky performance status of ≥60.
Descripción

have an karnofsky performance status of ≥60.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0206065
women of childbearing potential (<1 year post-menopausal unless surgically sterilized) and sexually active males must have a negative urine pregnancy test, and agree to use an effective barrier method of birth control (i.e. latex condom, diaphragm, cervical cap, etc) to avoid pregnancy.
Descripción

women of childbearing potential (<1 year post-menopausal unless surgically sterilized) and sexually active males must have a negative urine pregnancy test, and agree to use an effective barrier method of birth control (i.e. latex condom, diaphragm, cervical cap, etc) to avoid pregnancy.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3831118
UMLS CUI [2]
C0032961
UMLS CUI [3]
C0700589
able to comply with study procedures and follow-up examinations.
Descripción

able to comply with study procedures and follow-up examinations.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1321605
have adequate organ function as indicated by the following laboratory values, obtained within 7 days prior to registration: parameter required value (is units) renal serum creatinine <1.1 mg/dl hepatic serum bilirubin <2 x uln ast and alt ≤5 x uln uln = institutional upper limit of normal. inclusion laboratory values
Descripción

have adequate organ function as indicated by the following laboratory values, obtained within 7 days prior to registration: parameter required value (is units) renal serum creatinine <1.1 mg/dl hepatic serum bilirubin <2 x uln ast and alt ≤5 x uln uln = institutional upper limit of normal. inclusion laboratory values

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201976
UMLS CUI [2]
C1278039
UMLS CUI [3]
C0201899
UMLS CUI [4]
C0201836
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with pre-existing myelodysplastic syndrome, or with antecedent hematologic disorder of >3 months duration, will be excluded. those with concomitant myelodysplasia/trilineage dysplasia noted at the time of diagnosis of aml will be eligible 74
Descripción

patients with pre-existing myelodysplastic syndrome, or with antecedent hematologic disorder of >3 months duration, will be excluded. those with concomitant myelodysplasia/trilineage dysplasia noted at the time of diagnosis of aml will be eligible 74

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3463824
UMLS CUI [2]
C0018939
have secondary aml (aml following chemotherapy or radiation therapy).
Descripción

have secondary aml (aml following chemotherapy or radiation therapy).

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0280449
have an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment.
Descripción

have an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009488
have a psychiatric disorder(s) that would interfere with consent, study participation or follow-up.
Descripción

have a psychiatric disorder(s) that would interfere with consent, study participation or follow-up.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
are receiving other chemotherapy or corticosteroids (unless the latter is administered at a low dose for pre-medication purposes or for the treatment of chronic conditions - e.g., rheumatoid arthritis).
Descripción

are receiving other chemotherapy or corticosteroids (unless the latter is administered at a low dose for pre-medication purposes or for the treatment of chronic conditions - e.g., rheumatoid arthritis).

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C0001617
have received prior treatment for leukemia. patients who have received growth factors, cytokine support, leukapheresis, hydroxyurea, or cranial irradiation will be allowed but must discontinue treatment at least 24 hours prior to beginning treatment with clofarabine. if used, hydroxyurea must be discontinued 48 hours prior to the initiation of chemotherapy.
Descripción

have received prior treatment for leukemia. patients who have received growth factors, cytokine support, leukapheresis, hydroxyurea, or cranial irradiation will be allowed but must discontinue treatment at least 24 hours prior to beginning treatment with clofarabine. if used, hydroxyurea must be discontinued 48 hours prior to the initiation of chemotherapy.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1514463
UMLS CUI [2]
C0018284
UMLS CUI [3]
C0199974
UMLS CUI [4]
C0023416
UMLS CUI [5]
C0020402
UMLS CUI [6]
C0079172
have any other severe concurrent disease (severe coronary artery disease (nyha class >ii), significant neurological disorder, uncontrolled diabetes, etc.), which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Descripción

have any other severe concurrent disease (severe coronary artery disease (nyha class >ii), significant neurological disorder, uncontrolled diabetes, etc.), which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
have active central nervous system involvement with leukemia.
Descripción

have active central nervous system involvement with leukemia.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1332884
other malignancy within the past year, with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin
Descripción

other malignancy within the past year, with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006826
Volver a la parte superior de la página

Similar models

Eligibility Acute Myeloid Leukemia NCT00081822

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
AML
Item
have newly diagnosed aml (fab classification types m0-m2 or m4-m7 or who classification) excluding acute promyelocytic leukemia (apl) or aml with any of the following chromosomal translocations: t(15;17)(q22;q21); t(11;17)(q23;q21); t(11;17)(q13;q21); t(5;17)(q32;q12)..
boolean
C0023467 (UMLS CUI [1])
C0023487 (UMLS CUI [2])
C3688712 (UMLS CUI [3])
C1515708 (UMLS CUI [4])
C2825131 (UMLS CUI [5])
blasts in the bone marrow
Item
have greater than or equal to 20% blasts in the bone marrow.
boolean
C1982687 (UMLS CUI [1])
cellularity in the bone marrow
Item
have greater than or equal to 20% cellularity in the bone marrow.
boolean
C1561532 (UMLS CUI [1])
informed consent
Item
provide written informed consent.
boolean
C0021430 (UMLS CUI [1])
age
Item
must be 60-75 years of age at diagnosis.
boolean
C0001779 (UMLS CUI [1])
karnofsky performance status
Item
have an karnofsky performance status of ≥60.
boolean
C0206065 (UMLS CUI [1])
pregnancy and contraception
Item
women of childbearing potential (<1 year post-menopausal unless surgically sterilized) and sexually active males must have a negative urine pregnancy test, and agree to use an effective barrier method of birth control (i.e. latex condom, diaphragm, cervical cap, etc) to avoid pregnancy.
boolean
C3831118 (UMLS CUI [1])
C0032961 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
compliance
Item
able to comply with study procedures and follow-up examinations.
boolean
C1321605 (UMLS CUI [1])
organ function
Item
have adequate organ function as indicated by the following laboratory values, obtained within 7 days prior to registration: parameter required value (is units) renal serum creatinine <1.1 mg/dl hepatic serum bilirubin <2 x uln ast and alt ≤5 x uln uln = institutional upper limit of normal. inclusion laboratory values
boolean
C0201976 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
Item Group
C0680251 (UMLS CUI)
myelodysplastic syndrome or with antecedent hematologic disorder
Item
patients with pre-existing myelodysplastic syndrome, or with antecedent hematologic disorder of >3 months duration, will be excluded. those with concomitant myelodysplasia/trilineage dysplasia noted at the time of diagnosis of aml will be eligible 74
boolean
C3463824 (UMLS CUI [1])
C0018939 (UMLS CUI [2])
secondary aml
Item
have secondary aml (aml following chemotherapy or radiation therapy).
boolean
C0280449 (UMLS CUI [1])
systemic infection
Item
have an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment.
boolean
C0009488 (UMLS CUI [1])
psychiatric disorder(s) that would interfere with consent, study participation or follow-up
Item
have a psychiatric disorder(s) that would interfere with consent, study participation or follow-up.
boolean
C0021430 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
chemotherapy or corticosteroids
Item
are receiving other chemotherapy or corticosteroids (unless the latter is administered at a low dose for pre-medication purposes or for the treatment of chronic conditions - e.g., rheumatoid arthritis).
boolean
C0392920 (UMLS CUI [1])
C0001617 (UMLS CUI [2])
prior therapy for leukemia
Item
have received prior treatment for leukemia. patients who have received growth factors, cytokine support, leukapheresis, hydroxyurea, or cranial irradiation will be allowed but must discontinue treatment at least 24 hours prior to beginning treatment with clofarabine. if used, hydroxyurea must be discontinued 48 hours prior to the initiation of chemotherapy.
boolean
C1514463 (UMLS CUI [1])
C0018284 (UMLS CUI [2])
C0199974 (UMLS CUI [3])
C0023416 (UMLS CUI [4])
C0020402 (UMLS CUI [5])
C0079172 (UMLS CUI [6])
severe concurrent disease
Item
have any other severe concurrent disease (severe coronary artery disease (nyha class >ii), significant neurological disorder, uncontrolled diabetes, etc.), which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
cns leukemia
Item
have active central nervous system involvement with leukemia.
boolean
C1332884 (UMLS CUI [1])
malignancy
Item
other malignancy within the past year, with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin
boolean
C0006826 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial